Ligand Pharmaceuticals

Ligand Pharmaceuticals is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company's business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. The Company's business model is based on doing what Ligand does best: drug discovery, early-stage drug development, product reformulation and partnering. 
The Company's technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases, such as hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis (FSGS) and osteoporosis.

Company Growth (employees)
Type
Public
HQ
San Diego, US
Size (employees)
22 (est)+5%
Website
ligand.com
Ligand Pharmaceuticals is headquartered in San Diego, US

Key People at Ligand Pharmaceuticals

John L. Higgins

John L. Higgins

CEO

Ligand Pharmaceuticals Office Locations

Ligand Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
3911 Sorrento Valley Blvd

Ligand Pharmaceuticals Data and Metrics

Ligand Pharmaceuticals Financial Metrics

Ligand Pharmaceuticals's revenue was reported to be $109 m in FY, 2016 which is a 52% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

109 m

Revenue growth (FY, 2015 - FY, 2016), %

52%

Gross profit (FY, 2016)

103.4 m

Gross profit margin (FY, 2016), %

95%

Net income (FY, 2016)

(1.6 m)

EBIT (FY, 2016)

(2.4 m)

Market capitalization (22-Jun-2017)

2.6 b

Closing share price (22-Jun-2017)

120.2

Cash (31-Dec-2016)

18.8 m
Ligand Pharmaceuticals's current market capitalization is $2.6 b.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

49 m64.5 m71.9 m109 m

Revenue growth, %

32%11%52%

Cost of goods sold

5.6 m

Gross profit

43.2 m55.4 m66.1 m103.4 m

Gross profit Margin, %

88%86%92%95%

Operating expense total

34 m44.9 m44.6 m65.1 m

EBIT

14.9 m19.6 m27.3 m(2.4 m)

EBIT margin, %

31%30%38%(2%)

Interest expense

2.1 m4.9 m11.8 m12.2 m

Income tax expense

(10.3 m)

Net Income

11.4 m10.9 m254.9 m(1.6 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

11.6 m160.2 m97.4 m18.8 m

Accounts Receivable

2.2 m12.6 m6.2 m14.7 m

Inventories

1.4 m269 k1.6 m1.9 m

Current Assets

24.9 m185.2 m215.6 m163.1 m

PP&E

867 k486 k372 k1.8 m

Goodwill

12.2 m12.2 m12.2 m72.2 m

Total Assets

104.7 m258 m533.9 m601.6 m

Accounts Payable

4 m7.7 m4.1 m2.7 m

Current Liabilities

28.9 m22.8 m20.8 m227.1 m

Additional Paid-in Capital

718 m680.7 m701.5 m769.7 m

Retained Earnings

(671.3 m)(659.3 m)(402 m)(431.1 m)

Total Equity

24.4 m304.4 m341.3 m

Financial Leverage

10.6 x1.8 x1.8 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

11.4 m10.9 m254.9 m(1.6 m)

Depreciation and Amortization

2.7 m2.7 m2.6 m10.6 m

Accounts Receivable

2.4 m(10 m)6.5 m(8.5 m)

Inventories

646 k4.4 m(401 k)(244 k)

Cash From Operating Activities

20.7 m20.6 m41.7 m63 m

Purchases of PP&E

(6 k)(93 k)(1.9 m)

Cash From Investing Activities

(5 m)(2 m)(112.9 m)(143.2 m)

Long-term Borrowings

(19.6 m)(9.4 m)

Cash From Financing Activities

(16.5 m)130 m8.4 m1.5 m

Interest Paid

1.8 m494 k1.8 m1.8 m

Income Taxes Paid

26 k18 k28 k38 k
Numbers are in $, USDY, 2016

Revenue/Employee

1.3 m

Financial Leverage

1.8 x

Ligand Pharmaceuticals Market Value History

Ligand Pharmaceuticals Online and Social Media Presence

Ligand Pharmaceuticals Company Life and Culture

You may also be interested in